Market Research Logo

Multiple Myeloma Therapeutics in Major Developed Markets to 2021 - Growth Driven by Rising Prevalence, Continued Success of Revlimid and Emerging Supplementary Treatments

Multiple Myeloma Therapeutics in Major Developed Markets to 2021 - Growth Driven by Rising Prevalence, Continued Success of Revlimid and Emerging Supplementary Treatments

Summary


Multiple Myeloma (MM) is a hematological malignancy characterized by the proliferation of plasma cells in the bone marrow. It is the second-most frequently diagnosed hematological malignancy, with an annual prevalence in the US of about 45,000. The disease is considered incurable, although the past decade has seen significant improvements in therapy, driven by a greater understanding of pathophysiology. Many of the leading drugs in the market were approved over the past 10–15 years, and have improved median survival rates by about 50%.

The MM pipeline contains 267 products in active development, encompassing a range of molecule types and therapeutic targets. The innovation that has characterized the market over recent years is also clearly present in the current pipeline, with a strong presence of novel, targeted products.

Scope

  • The MM market landscape has undergone significant change over the past two decades.
  • Which classes of drug have emerged to dominate the market?
  • What survival benefits have these drugs produced?
  • How do the leading marketed therapies compare clinically?
  • The pipeline contains a range of molecule types and molecular targets not present in the current market, including a strong focus on therapies targeting common oncogenic pathways, such as the Phosphoinositide 3-Kinase/Protein Kinase B (PI3K/Akt) pathway.
  • Which molecular targets appear most frequently in the pipeline?
  • How will the new therapies be positioned in the treatment of MM?
  • How have selected late-stage pipeline therapies performed in clinical trials?
  • MM clinical trials have an overall attrition rate of 78%.
  • What are the failure rates for individual Phases of clinical development?
  • How do MM clinical trial characteristics, including failure rate, duration, and size compare against oncology and industry averages?
  • The MM market is forecast to rise from a value of $7.3 billion in 2014 to $8.9 billion in 2021, at a CAGR of 2.9% across the eight major markets assessed.
  • How much of a role will disease prevalence and new product approvals play in market growth?
  • Will generic competition have a significant impact on the market over the forecast period?
  • There have been 39 licensing deals and 22 co-development deals pertaining to MM products since 2006.
  • Which territories show the most deal activity?
  • What were the trends in deal completion by product stage of development?
  • What were the conditions of the key licensing or co-development deals to take place in MM?
Reasons to buy
  • Understand the current clinical and commercial landscape through a comprehensive study of disease pathogenesis, diagnosis, prognosis, and the current treatment algorithm used in MM.
  • Assess the safety and efficacy of current treatment options, with extensive product profiles on prominent marketed therapies and a heatmap directly comparing safety and efficacy data.
  • Analyze the MM pipeline and stratify by stage of development, molecule type, and molecular target. The most promising late-stage therapies are profiled and assessed in terms of clinical performance and competitiveness, alongside a single-product forecast.
  • Predict growth in market size in eight major markets, with in-depth market forecasting from 2014–2021. The forecasts will provide an understanding of how epidemiology trends, new drug entry, and patent expirations will influence market value.
  • Identify commercial opportunities in the MM deals landscape by analyzing trends in licensing and co-development deals, and by profiling the most significant deals that have occurred in this indication in recent years.


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Disease Introduction
2.2 Etiology
2.3 Pathophysiology
2.4 Symptoms
2.5 Diagnosis and Classification
2.6 Epidemiology
2.7 Prognosis and Disease Staging
2.8 Treatment Options
2.8.1 Treatment Algorithm
2.8.2 Initial Therapy for Newly Diagnosed Symptomatic Disease
2.8.3 Maintenance Therapy
2.8.4 Therapy for Relapsed or Refractory Myeloma
3 Marketed Products
3.1 Overview
3.2 Immunomodulatory Agents
3.2.1 Thalomid (thalidomide) – Celgene
3.2.2 Revlimid (lenalidomide) – Celgene
3.2.3 Pomalyst (pomalidomide) – Celgene
3.3 Proteasome Inhibitors
3.3.1 Velcade (bortezomib) – Millennium Pharmaceuticals/Takeda
3.3.2 Kyprolis (carfilzomib) – Onyx
3.4 Histone Deacetylase Inhibitors
3.4.1 Farydak (panobinostat) – Novartis
3.5 Chemotherapy
3.5.1 Doxil (doxorubicin HCl liposome injection) – Janssen
3.6 Comparative Efficacy and Safety of Marketed Products
4 Pipeline Products
4.1 Overall Pipeline
4.2 Pipeline Analysis by Molecular Target
4.3 Clinical Trials
4.3.1 Failure Rate
4.3.2 Patient Enrolment and Clinical Trial Size
4.3.3 Duration
4.4 Competitive Clinical Trials Metrics Analysis
4.5 Promising Drug Candidates in the Pipeline
4.5.1 Ixazomib Citrate – Millennium Pharmaceuticals
4.5.2 Zolinza (vorinostat) – Merck
4.5.3 ARRY-520 (filanesib) – Array Biopharma
4.5.4 Aplidin (plitidepsin) – PharmaMar
4.5.5 Elotuzumab – AbbVie and Bristol Myers Squibb
4.5.6 Daratumumab – Johnson & Johnson
4.6 Heat Map for Pipeline Products
5 Market Forecast to 2021
5.1 Geographical Markets
5.2 Global Market
5.3 North America
5.3.1 Treatment Usage Patterns
5.3.2 Annual Cost of Therapy
5.3.3 Market Size
5.4 Top Five EU Markets
5.4.1 Treatment Usage Patterns
5.4.2 Annual Cost of Therapy
5.4.3 Market Size
5.5 Japan
5.5.1 Treatment Usage Patterns
5.5.2 Annual Cost of Therapy
5.5.3 Market Size
5.6 Drivers and Barriers for the Disease Market
5.6.1 Drivers
5.6.2 Barriers
6 Deals and Strategic Consolidations
6.1 Licensing Deals
6.1.1 Genmab Enters into Licensing Agreement with Janssen Biotech for Daratumumab
6.1.2 Genentech Enters into Licensing Agreement with Seattle Genetics – Now Terminated
6.1.3 OncoPep Enters into Licensing Agreement with Dana-Farber Cancer Institute for Cancer Vaccine Technology
6.1.4 PharmaMar Enters into Licensing Agreement with Chugai for Aplidin
6.1.5 Onyx Enters into Licensing Agreement with Ono Pharma for Kyprolis and Oprozomib
6.2 Co-development Deals
6.2.1 Celgene Enters into Co-development Agreement with MedImmune
6.2.2 Acetylon Enters into Co-development Agreement with Leukemia & Lymphoma Society
6.2.3 Boehringer Ingelheim Enters into Collaboration Agreement with Micromet
6.2.4 Multiple Myeloma Research Foundation Enters into Co-development Agreement with Onyx
6.2.5 Dana-Farber Cancer Institute Enters into Agreement with MannKind
6.2.6 Nordic Nanovector Enters into Co-development Agreement with Affibody
7 Appendix
7.1 All Pipeline Drugs by Phase of Development
7.1.1 Discovery
7.1.2 Preclinical
7.1.3 IND/CTA-filed
7.1.4 Phase I
7.1.5 Phase II
7.1.6 Phase III
7.1.7 Pre-registration
7.2 Market Forecasts to 2021
7.2.1 Global
7.2.2 US
7.2.3 Canada
7.2.4 UK
7.2.5 France
7.2.6 Germany
7.2.7 Italy
7.2.8 Spain
7.2.9 Japan
7.3 Bibliography
7.4 Abbreviations
7.5 Research Methodology
7.5.1 Secondary Research
7.5.2 Marketed Product Profiles
7.5.3 Late-Stage Pipeline Candidates
7.5.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products
7.5.5 Forecasting Model
7.5.6 Deals Data Analysis
7.6 Expert Panel Validation
7.7 Contact Us
7.8 Disclaimer
List of Tables
Table 1: Multiple Myeloma Therapeutics Market, Global, Initial Screening in Suspected Myeloma Patients
Table 2: Multiple Myeloma Therapeutics Market, Global, Diagnostic Criteria for MGUS, Asymptomatic Myeloma and Symptomatic Myeloma
Table 3: Multiple Myeloma Therapeutics Market, Global, Myeloma-Related Organ or Tissue Impairment
Table 4: Multiple Myeloma Therapeutics Market, Global, Disease Staging, Durie-Salmon Staging System
Table 5: Multiple Myeloma Therapeutics Market, Global, Prognostic Factors
Table 6: Multiple Myeloma Therapeutics Market, Global, Prognostic Factors
Table 7: Multiple Myeloma Therapeutics Market, Global, Pipeline Products, Discovery, 2015
Table 8: Multiple Myeloma Therapeutics Market, Global, Pipeline Products, Preclinical, 2015
Table 9: Multiple Myeloma Therapeutics Market, Global, Pipeline Products, IND/CTA-filed, 2015
Table 10: Multiple Myeloma Therapeutics Market, Global, Pipeline Products, Phase I, 2015
Table 11: Multiple Myeloma Therapeutics Market, Global, Pipeline Products, Phase II, 2015
Table 12: Multiple Myeloma Therapeutics Market, Global, Pipeline Products, Phase III, 2015
Table 13: Multiple Myeloma Therapeutics Market, Global, Pipeline Products, Pre-registration, 2015
Table 14: Multiple Myeloma Therapeutics Market, Global, Market Forecast, 2014–2021
Table 15: Multiple Myeloma Therapeutics Market, US, Market Forecast, 2014–2021
Table 16: Multiple Myeloma Therapeutics Market, Canada, Market Forecast, 2014–2021
Table 17: Multiple Myeloma Therapeutics Market, UK, Market Forecast, 2014–2021
Table 18: Multiple Myeloma Therapeutics Market, France, Market Forecast, 2014–2021
Table 19: Multiple Myeloma Therapeutics Market, Germany, Market Forecast, 2014–2021
Table 20: Multiple Myeloma Therapeutics Market, Italy, Market Forecast, 2014–2021
Table 21: Multiple Myeloma Therapeutics Market, Spain, Market Forecast, 2014–2021
Table 22: Multiple Myeloma Therapeutics Market, Japan, Market Forecast, 2014–2021
1.2 List of Figures
Figure 1: Multiple Myeloma Therapeutics Market, Global, Average Number of New Cases per Year and Age Specific Incidence Rates, UK, 2009–2011
Figure 2: Multiple Myeloma Therapeutics Market, Global, Treatment Algorithm for Myeloma
Figure 3: Multiple Myeloma Therapeutics Market, Global, Heat Map for Initial Treatment – Efficacy
Figure 4: Multiple Myeloma Therapeutics Market, Global, Heat Map for Initial Treatment – Safety
Figure 5: Multiple Myeloma Therapeutics Market, Global, Heat Map for Maintenance Treatment
Figure 6: Multiple Myeloma Therapeutics Market, Global, Heat Map for Relapsed or Refractory Multiple Myeloma – Efficacy
Figure 7: Multiple Myeloma Therapeutics Market, Global, Heat Map for Relapsed or Refractory Multiple Myeloma – Safety
Figure 8: Multiple Myeloma Therapeutics Market, Global, Overview of Pipeline Products
Figure 9: Multiple Myeloma Therapeutics Market, Global, Target Families in the Pipeline
Figure 10: Multiple Myeloma Therapeutics Market, Global, Clinical Trial Overall Attrition Rate and Failure Rate by Phase, 2006–2015
Figure 11: Multiple Myeloma Therapeutics Market, Global, Clinical Trial Overall Attrition Rate and Failure Rate by Phase and Molecule Type, 2006–2015
Figure 12: Multiple Myeloma Therapeutics Market, Global, Clinical Trial Attrition Rate and Failure Rate by Phase and Molecular Target, 2006–2015
Figure 13: Multiple Myeloma Therapeutics Market, Global, Clinical Trial Size per Product by Molecule Type, 2006–2015
Figure 14: Multiple Myeloma Therapeutics Market, Global, Clinical Trial Size per Individual Trial by Molecule Type, 2006–2015
Figure 15: Multiple Myeloma Therapeutics Market, Global, Clinical Trial Size per Product by Molecular Target, 2006–2015
Figure 16: Multiple Myeloma Therapeutics Market, Global, Clinical Trial Size per Individual Trial by Molecular Target, 2006–2015
Figure 17: Multiple Myeloma Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type, 2006–2015
Figure 18: Multiple Myeloma Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target, 2006–2015
Figure 19: Multiple Myeloma Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type
Figure 20: Multiple Myeloma Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecular Target
Figure 21: Multiple Myeloma Therapeutics Market, Global, Ixazomib Citrate Market Forecast, 2020–2021
Figure 22: Multiple Myeloma Therapeutics Market, Global, Zolinza Market Forecast, 2019–2021
Figure 23: Multiple Myeloma Therapeutics Market, Global, ARY-520 Market Forecast, 2020–2021
Figure 24: Multiple Myeloma Therapeutics Market, Global, Elotuzumab Market Forecast, 2017–2021
Figure 25: Multiple Myeloma Therapeutics Market, Global, Daratumumab Market Forecast, 2017–2021
Figure 26 : Multiple Myeloma Therapeutics Market, Global, Pipeline Heat Map, 2015
Figure 27: Multiple Myeloma Therapeutics Market, Global, Treatment Patterns (‘000) and Market Size ($bn), 2014–2021
Figure 28: Multiple Myeloma Therapeutics Market, North America, Treatment Patterns, 2014–2021
Figure 29: Multiple Myeloma Therapeutics Market, North America, Annual Cost of Therapy ($), 2014–2021
Figure 30: Multiple Myeloma Therapeutics Market, North America, Market Size, 2014–2021
Figure 31: Multiple Myeloma Therapeutics Market, EU, Treatment Patterns, 2014–2021
Figure 32: Multiple Myeloma Therapeutics Market, EU, Annual Cost of Therapy ($), 2014–2021
Figure 33: Multiple Myeloma Therapeutics Market, EU, Market Size, 2014–2021
Figure 34: Multiple Myeloma Market, Japan, Treatment Usage Patterns (‘000), 2014–2021
Figure 35: Multiple Myeloma Market, Japan, Annual Cost of Therapy ($), 2014–2021
Figure 36: Multiple Myeloma Therapeutics Market, Japan, Market Size ($m), 2014–2021
Figure 37: Multiple Myeloma Therapeutics Market, Global, Licensing Deals by Region, 2006–2015
Figure 38: Multiple Myeloma Therapeutics Market, Global, Licensing Deals by Deal Value ($m), 2006–2015
Figure 39: Multiple Myeloma Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value ($m) and Aggregate Upfront Payment Value ($m), 2006–2015
Figure 40: Multiple Myeloma Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value ($m) and Upfront Payment Value ($m), 2006–2015
Figure 41: Multiple Myeloma Therapeutics Market, Global, Licensing Deals by Molecule Type, Stage of Development and Aggregate Deal Value ($m), 2006–2015
Figure 42: Multiple Myeloma Therapeutics Market, Global, Licensing Deals by Molecular Target, 2006–2015
Figure 43: Multiple Myeloma Therapeutics Market, Global, Co-development Deals by Region, 2006–2015
Figure 44: Multiple Myeloma Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-development Deals by Year, 2006–2015
Figure 45: Multiple Myeloma Therapeutics Market, Global, Co-development Deals by Stage of Development, 2006–2015
Figure 46: Multiple Myeloma Therapeutics Market, Global, Co-development Deals by Molecule Type and Stage of Development, 2006–2015
Figure 47: Multiple Myeloma Therapeutics Market, Global, Co-development Deals by Molecular Target, 2006–2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report